ESMO

CAR-T Cell Therapy Shows Promise in Relapsed/Refractory Solid Cancers

September 11th 2022, 5:00pm

Article

BNT211-01, a novel CAR-T cell therapy, was efficacious in treating patients with CLDN6-positive, relapsed/refractory solid cancers, according to a small clinical trial.

Trodelvy May Fulfill Unmet Need for Subset of Patients With Metastatic Breast Cancer

September 10th 2022, 5:00pm

Article

Compared to physician’s choice of treatment, Trodelvy improved survival and quality of life in pretreated patients with HR positive/HER2 negative metastatic breast cancer.

Adding the Novel Drug Oleclumab to Imfinzi and Chemotherapy Fails to Improve TNBC Outcomes

September 9th 2022, 9:00pm

Article

Adding the novel drug oleclumab to Imfinzi and chemotherapy for the frontline treatment of advanced triple-negative breast cancer did not improve clinical outcomes, according to recent study findings.

Rubraca Staves Off Disease Progression Better Than Chemotherapy in BRCA-Mutant Relapsed Ovarian Cancer, Research Shows

September 9th 2022, 7:00pm

Article

Rubraca improved progression-free survival in patients with BRCA1/2-mutant, platinum-sensitive, relapsed ovarian cancer, according to findings from the ARIEL4 clinical trial.

Survivorship Program Increases Satisfaction, Improves Quality of Life in Recurrent Breast Cancer

October 2nd 2019, 1:00am

Article

“Survivors living with recurrent breast cancer have unique needs and programs that address these needs can enhance patient satisfaction,” the study authors wrote.

Addition of CDK4/6 Inhibitors to Faslodex Improves Survival in Breast Cancer Subgroup

September 30th 2019, 5:49pm

Article

Two studies showed that adding a CDK4/6 inhibitor to treatment with Faslodex improved survival among women with hormone receptor-positive, human epidermal growth factor2-negative advanced breast cancer.

Frontline Tagrisso Improves Survival Among Specific Subgroup of Patients with NSCLC

September 30th 2019, 12:00am

Article

First-line Tagrisso significantly extended overall survival compared with first generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer, according to results from the phase 3 FLAURA study.

Opdivo-Yervoy Combination Induces Long-Term Survival in Metastatic Melanoma

September 29th 2019, 10:00pm

Article

One in two patients with metastatic melanoma is alive five years following treatment with Opdivo plus Yervoy, according to long-term follow-up of the phase 3 CheckMate 067 trial.

Frontline Zejula Maintenance Therapy Improves Survival in Advanced Ovarian Cancer

September 29th 2019, 6:00pm

Article

Frontline maintenance therapy with Zejula lengthened time without disease progression among women with newly diagnosed, advanced ovarian cancer, according to findings from the phase 3 PRIMA study.

Frontline Opdivo, Yervoy May Improve Survival in Non-Small Cell Lung Cancer

September 29th 2019, 1:00am

Article

First-line treatment with Opdivo plus low-dose Yervoy improved survival among patients with advanced NSCLC compared to chemotherapy, according to results from the CheckMate-227 trial.